Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityMNI / McClatchy Co. (THE) (579489105)
CEOForman Craig I
IndustryNewspapers: Publishing, or Publishing and Printing
Institutional Owners37
Institutional Shares2,070,693 - 38.86%
Common Shares Outstanding5,328,547 shares (as of 2018-04-01)
Institutional Value$ 19,783,000 USD
Related 499040AN3 / Knight Ridder Inc 4.625% Notes 11/01/14
499040AP8 / Knight Ridder Inc 5.75% Notes 9/1/2017
499040AL7 / Knight Ridder Inc 6.875% Debentures 03/15/29
499040AH6 / Knight Ridder Inc 7.150% Debentures 11/01/27

Institutional Stock Ownership and Shareholders()

McClatchy Co. (THE) (AMEX:MNI) has 37 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,070,693 shares. Largest shareholders include Royce & Associates LLC, Susquehanna International Group, Llp, Dimensional Fund Advisors Lp, Credit Suisse Ag/, BlackRock Institutional Trust Company, N.A., BlackRock Inc., Vanguard Group Inc, Bridgeway Capital Management Inc, Highbridge Capital Management Llc, and Renaissance Technologies LLC.
McClatchy Co. (THE) (AMEX:MNI) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 5,000 5,000 0.00 45 46 2.22
2018-04-12 13F-HR ACADIAN ASSET MANAGEMENT LLC 4,858 4,858 0.00 43 45 4.65
2018-04-30 13F-HR TCI Wealth Advisors, Inc. 36 36 0.00 0 0
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 18,980 18,980 0.00 169 176 4.14
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 63 63 0.00 1 1 0.00
2018-05-14 13F-HR MORGAN STANLEY 1,885 585 -68.97 17 6 -64.71
2018-05-09 13F-HR BlackRock Inc. 129,464 128,217 -0.96 1,156 1,186 2.60
2018-05-08 13F-HR US BANCORP \DE\ 1,417 971 -31.47 13 9 -30.77
2018-05-11 13F-HR MACQUARIE GROUP LTD 12,100 112
2018-05-15 13F-HR Spears Abacus Advisors LLC 17,276 17,276 0.00 154 160 3.90
2017-02-10 13F-HR BlackRock Investment Management, LLC 934 875 -6.32 15 12 -20.00
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 34,331 34,032 -0.87 306 314 2.61
2017-02-10 13F-HR BlackRock Fund Advisors 15,258 15,940 4.47 246 210 -14.63
2018-05-15 13F-HR HBK INVESTMENTS L P 23,200 0 -100.00 207 0 -100.00
2018-05-11 13F-HR GARDNER RUSSO & GARDNER LLC 2,500 0 -100.00 22 0 -100.00
2018-05-03 13F-HR BRONFMAN E.L. ROTHSCHILD, L.P. 707 707 0.00 6 7 16.67
2018-05-15 13F-HR UBS Group AG 1,439 9 -99.37 13 0 -100.00
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 150 150 0.00 1 1 0.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 2,700 1,134 -58.00 24 11 -54.17
2018-05-15 13F-HR CREDIT SUISSE AG/ 135,600 136,055 0.34 1,211 1,258 3.88
2018-05-09 13F-HR NORTHERN TRUST CORP 12,005 12,113 0.90 107 112 4.67
2018-04-20 13F-HR Seacrest Wealth Management, Llc 410 410 0.00 4 4 0.00
2018-05-15 13F-HR VANGUARD GROUP INC 113,509 124,265 9.48 1,014 1,150 13.41
2018-05-15 13F-HR DEUTSCHE BANK AG\ 220 220 0.00 1 2 100.00
2018-05-14 13F-HR Renaissance Technologies LLC 42,130 38,230 -9.26 376 354 -5.85
2018-05-15 13F-HR HIGHBRIDGE CAPITAL MANAGEMENT LLC 30,467 40,154 31.80 272 371 36.40
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 130,967 132,244 0.98 2,112 1,743 -17.47
2018-05-14 13F-HR Archford Capital Strategies, LLC 0 1,247 0 11
2017-02-10 13F-HR BlackRock Advisors LLC 1,090 1,090 0.00 18 14 -22.22
2018-05-14 13F-HR Royce & Associates LLC 560,398 543,306 -3.05 5,004 5,026 0.44
2018-04-17 13F-HR Calton & Associates, Inc. 34 0 -100.00 0 0
2017-02-10 13F-HR BlackRock Group LTD 8,926 8,926 0.00 144 118 -18.06
2018-05-01 13F-HR Hanson McClain, Inc. 21 21 0.00 0 0
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 247,692 409,759 65.43 2,212 3,790 71.34
2018-05-23 13F-HR/A Allianz Asset Management AG 241,104 0 -100.00 2,153 0 -100.00
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 51,545 51,545 0.00 460 477 3.70
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 292,117 282,859 -3.17 2,609 2,616 0.27
2018-04-23 13F-HR Sterling Investment Advisors, Ltd. 100 100 0.00 1 1 0.00
2018-05-11 13F-HR STIFEL FINANCIAL CORP 11,963 11,963 0.00 109 114 4.59
2018-05-15 13F-HR PANAGORA ASSET MANAGEMENT INC 100 100 0.00 1 1 0.00
2018-05-15 13F-HR WHITEBOX ADVISORS LLC 38,953 35,153 -9.76 348 325 -6.61

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

NY Times (NYT) Trades Above Industry for 6 Months: Here's Why

2018-07-04 zacks
The New York Times Company (NYT - Free Report) has come a long way from being a sole provider of news content and advertising on print publications. The company is no longer restricted to print. As readers swarmed to the Internet, advertisers followed suit and so did newspaper companies. Trimmed print operations paved way for online publications that led to the development of paywalls. Industry experts cited that focus on new avenues of revenue generation is necessary to counter the dwindling print advertising revenues. (9-0)

NY Times (NYT) Digitalization Mantra Paying Off Quite Well

2018-06-11 zacks
The U.S. newspaper publishing industry is no longer restricted to print. This is largely because rampant technological advancements and the steady adoption of the same have opened up multiple ways by which the industry can reach its target audience. The New York Times Company (NYT - Free Report) is fast acclimatizing to the changing face of the multiplatform media universe and has already included mobile and reader application products in portfolio. (34-0)

How a NY architect offers a window into Trump deals in Eastern Europe

2018-06-06 cnbc
As Robert Mueller looks ever more closely at President Donald Trump's foreign business ties, one former associate has remained outside the spotlight despite playing a key role in Trump's quest for real estate deals in former Soviet lands. (4-0)

Zacks Industry Outlook Highlights: Gannett, McClatchy, tronc, New Media Investment Group and New York Times

2018-06-06 zacks
Chicago, IL – June 6, 2018 – Today, Zacks Equity Research discusses the Industry: Publishing, Part 2, including Gannett Co., Inc. (GCI - Free Report) , The McClatchy Company (MNI - Free Report) , tronc, Inc. (TRNC - Free Report) , New Media Investment Group (NEWM - Free Report) and The New York Times Company (NYT - Free Report) . (53-0)

Is Digitalization Giving Publishing Stocks a Facelift?

2018-06-05 zacks
The U.S. newspaper publishing industry is no longer restricted to print. This is largely because rampant technological advancements have opened up multiple ways in which the industry can reach its target audience. That said, it is increasingly becoming obvious that newspaper companies cannot solely rely on print or digital advertising but need to diversify their revenue streams focusing on video content, events and paid-for-products. (90-0)

CUSIP: 579489105